Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies.
- DOI
- 10.1016/j.jhepr.2025.101350
- Published
- 2025 Jun
- Container
- JHEP reports : innovation in hepatology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jhepr.2025.101350,
title = {Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies.},
author = {Finn RS and Gu K and Chen X and Merle P and Lee KH and Bouattour M and Cao P and Wang W and Cheng AL and Zhu L and Lim HY and Kudo M and Pan Y and Chang TT and Edeline J and Li W and Yang P and Li C and Li J and Siegel AB and Qin S},
year = {2025},
journal = {JHEP reports : innovation in hepatology},
doi = {10.1016/j.jhepr.2025.101350},
url = {https://doi.org/10.1016/j.jhepr.2025.101350}
}RIS
TY - JOUR TI - Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies. AU - Finn RS AU - Gu K AU - Chen X AU - Merle P AU - Lee KH AU - Bouattour M AU - Cao P AU - Wang W AU - Cheng AL AU - Zhu L AU - Lim HY AU - Kudo M AU - Pan Y AU - Chang TT AU - Edeline J AU - Li W AU - Yang P AU - Li C AU - Li J AU - Siegel AB AU - Qin S PY - 2025 JO - JHEP reports : innovation in hepatology DO - 10.1016/j.jhepr.2025.101350 UR - https://doi.org/10.1016/j.jhepr.2025.101350 ER -
APA
RS, F., K, G., X, C., P, M., KH, L., M, B., P, C., W, W., AL, C., L, Z., HY, L., M, K., Y, P., TT, C., J, E., W, L., P, Y., C, L., J, L., AB, S., & S, Q. (2025). Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies.. JHEP reports : innovation in hepatology. https://doi.org/10.1016/j.jhepr.2025.101350
Source records
- pubmed · retrieved 2026-09-26T18:20:13.134Z